Wednesday, July 27, 2011
Threshold Pharmaceuticals Inc., of Redwood City, Calif., said the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio started a 28-patient trial of TH-302 in combination with Avastin (bevacizumab, Roche AG) in patients with recurrent high-grade astrocytoma, including glioblastoma. The study will enroll patients whose disease has progressed following both combined modality treatment with radiation and temozolomide chemotherapy, as well as therapy with Avastin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.